Company Analysis Relief Therapeutics Holding AG
1. Summary
Advantages
- Price (3 $) is less than fair price (3.91 $)
- The stock's return over the last year (0%) is higher than the sector average (-15.09%).
Disadvantages
- Dividends (0%) are below the sector average (1.56%).
- The company's current efficiency (ROE=-31.07%) is lower than the sector average (ROE=13.38%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Relief Therapeutics Holding AG | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -11.3% | -1.2% |
| 90 days | 0% | -11.2% | -6.6% |
| 1 year | 0% | -15.1% | 6.9% |
RLFFD vs Sector: Relief Therapeutics Holding AG has outperformed the "Healthcare" sector by 15.09% over the past year.
RLFFD vs Market: Relief Therapeutics Holding AG has significantly underperformed the market by -6.91% over the past year.
Stable price: RLFFD is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: RLFFD with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (3 $) is lower than the fair price (3.91 $).
Price significantly below the fair price: The current price (3 $) is 30.3% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (31.32).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (53.47).
4.3. P/BV
P/BV vs Sector: The company's P/BV (111.83) is higher than that of the sector as a whole (3.11).
P/BV vs Market: The company's P/BV (111.83) is higher than that of the market as a whole (-8.35).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (3.24).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (4.74).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0) is lower than that of the sector as a whole (10.17).
EV/Ebitda vs Market: The company's EV/Ebitda (0) is lower than that of the market as a whole (28.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 125.38% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (125.38%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-29.36%).
5.4. ROE
ROE vs Sector: The company's ROE (-31.07%) is lower than that of the sector as a whole (13.38%).
ROE vs Market: The company's ROE (-31.07%) is lower than that of the market as a whole (4.9%).
5.5. ROA
ROA vs Sector: The company's ROA (-23.06%) is lower than that of the sector as a whole (6.25%).
ROA vs Market: The company's ROA (-23.06%) is lower than that of the market as a whole (16.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11.06%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.56%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
